SABS ▲ +1.5% - SAB Biotherapeutics, Inc. $SABS SABSW - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes SAB Biotherapeutics shares rose 1.5% following the company's announcement that it will present clinical data for SAB-142 at the 62nd Annual Meeting of the European Association for the Study of Diabetes, a major diabetes research conference. The presentation of new efficacy or safety data for its therapeutic candidate at a prominent medical conference typically attracts investor interest in biotech firms developing treatments in metabolic disease. 22-SEP-2026 08:30 AM ET